Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Blood

Volumn 100, Issue 7, 2002, Pages 2303-2320

  Douglas Rizzo, J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Lichtin, Alan E ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Woolf, Steven H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Seidenfeld, Jerome ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Bennett, Charles L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Cella, David ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Djulbegovic, Benjamin ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Goode, Matthew J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Jakubowski, Ann A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Lee, Stephanie J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Miller, Carole B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Rarick, Mark U ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Regan, David H ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Browman, George P ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Gordon, Michael S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Blue Cross and Blue Shield Association   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h Memorial Sloan Kettering Cancer Center ^*

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k ST AGNES HOSPITAL   (United States)

^l KAISER PERMANENTE   (United States)

^m JURAVINSKI CANCER CENTRE   (Canada)

ⁿ UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; MAJOR CLINICAL STUDY; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0036786902     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1767     Document Type: Review

References (69)

1. Agency for Health Care Policy and Research (AHCPR). AHCPR requests topic nominations for evidence reports and technology assessments: media advisory, November 28, 1997. Available at: http://www.ahcpr.gov/news/press/epcnompr.htm. Accessed October 27, 2000.
2. Agency for Health Care Policy and Research (AHCPR). AHCPR announces new evidence report topics: press release, October 29, 1998. Available at: http://www.ahcpr.gov/news/press/epctopic.htm. Accessed October 27, 2000.
3. Seidenfeld J, Aronson N, Piper MA, et al. Use of epoetin for anemia in oncology. Evidence Report/Technology Assessment No. 30. AHRQ Publication No. 01-E009. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290-97-0015. Rockville, MD: Agency for Healthcare Research and Quality. June 2001.
4. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment for anemia of cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
5. Medscape Hematology-Oncology. Available at: http://oncology.medscape.com/Home/Topics/oncology/oncology.html.
6. Cook DL, Guyatt GH, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1992;102(suppl 4):305S-311S.
7. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95:2S-4S.
8. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671-679.
9. Case DC Jr, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993;85:801-806.
10. Cascinu S, Fedell A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994;12:1058-1062.
11. Silvestris F, Romito A, Fanelli P, et al. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol. 1995;70:313-318.
12. Henry DH, Brooks BJ Jr, Case DC Jr, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am. 1995;1:252.
13. Kurz C, Marth C, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol. 1997;65:461-466.
14. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol. 1998;9:255-260.
15. Littlewood TJ, Bajetta E, Cella D, et al. Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1999;18:574a.
16. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
17. Fairclough DL, Gagnon D. The significance of missing data in clinical trials. Presented at the annual conference of the International Society for Quality of Life Research (ISOQOL), October 2000.
18. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
19. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res, 2002;11:207-221.
20. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol. 1993;49:172-176.
21. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:1147-1152.
22. Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994;29:1079-1084.
23. Henke M, Guttenberger R. Barke A. et al. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol. 1999;50:185-190.
24. Wurnig C, Windhager R, Schwameis E, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion. 1996;36:155-159.
25. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15:174-182.
26. Quirt I, Coutere F, Pichette R, et al. The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy: results of a randomized, double-blind, placebo-controlled clinical trial [abstract]. Blood. 1996;88:347a.
27. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80:396-402.
28. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-423.
29. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001;57:411-418.
30. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
31. Nguyen TV, Trinh GN. Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation [letter]. J Clin Oncol. 2002;20:878.
32. Silberstein PT, Witzig TE, Sloan JA, et al. Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group [abstract]. Proc Am Soc Clin Oncol. 2002;21:356a.
33. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001;84(suppl 1):17-23.
34. Kotasek D, Berg R, Poulsen E, et al. Randomized, double-blind, placebo controlled, phase I/Il dose finding study of Aranesp administered once every three weeks in solid tumor patients [abstract]. Blood. 2000;96:294a.
35. Pirker R, Vansteenkiste J, Gateley J, et al. A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. NESP 980297 Study Group [abstract]. Proc Am Soc Clin Oncol. 2001;20:394a.
36. Hedenus M, Hansen S, Dewey C, et al. A randomized, blinded, placebo-controlled, phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in patients with lymphoproliferative malignancies [abstract]. Proc Am Soc Clin Oncol. 2001;20:393a.
37. Glaspy JA, Jadeja J, Justice G, et al. Randomized, active-controlled, phase 1/2, dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001;20:387a.
38. Kotasek D, Albertsson M, Mackey J, et al. Randomized, double-blind, placebo-controlled, dosefinding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors. Darbepoetin alfa 980291 Study Group [abstract]. Proc Am Soc Clin Oncol. 2002;21:356a.
39. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998;16:3412-3425.
40. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr. 1996;129:656-660.
41. Albitar S, Meulders Q, Hammoud H, et al. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995;10(suppl 6):40-43.
42. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-583.
43. Casadevall N, Nataf J, Viron B, et al. Pure redcell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
44. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997;15:1218-1234.
45. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
46. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172-179.
47. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486-2494.
48. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070-1074.
49. Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma: a prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med. 1995;155:2069-2074.
50. Dammacco F, Silvestris F, Castoldi GL, et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res. 1998;28:127-134,
51. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) [abstract]. Blood. 1994;84(suppl):526a.
52. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995;86:4446-4453.
53. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood. 1996;87:2675-2682.
54. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(suppl 2):S2-8.
55. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist. 1996;1:140-150.
56. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol. 1994;21:21-28.
57. Stasi R, Brunetti M, Bussa S, et al. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol. 1997;19:197-201.
58. Kreuzer KA, Rockstroh JK, Jelkmann W, et al. Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol. 1997;96:235-239.
59. Takemasa A, Yorioka N, Ueda C, et al. Stimulation of tumour necrosis factor-alpha production by recombinant human erythropoietin may contribute to failure of therapy. Scand J Urol Nephrol. 2000;34:131-135.
60. Leon P, Jimenez M, Barona P, et al. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol. 1998;30:110-116.
61. Varan A, Buyukpamukcu M, Kutluk T, et al. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999;103:E16.
62. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer. 1998;77:1996-2002.
63. Gamucci T, Thorel MF, Frasca AM, et al. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer. 1993;29A(suppl 2):S13-14.
64. Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997;15:2715-2721.
65. Welch RS, James RD, Wilkinson PM, et al. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am. 1995;1:261.
66. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
67. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
68. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making. 1998;18:37-43.
69. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.